Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey

This study has been completed.
European Vision Institute Clinical Research Network
Information provided by (Responsible Party):
Santhera Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: June 26, 2013
Last updated: May 14, 2014
Last verified: May 2014

The objective of this survey is to establish the clinical course of vision loss and recovery in patients with a genetically confirmed diagnosis of Leber Hereditary Optic Neuropathy (LHON).

Visual acuity changes over time from onset of symptoms and from visual acuity nadir will be the main endpoint analysed.

The survey will collect historically documented visual acuity data for all patients at participating sites with a genetically confirmed diagnosis of LHON. No exclusion criteria apply. Patients are not required to attend the clinic for the survey.

Data will be collected in a completely anonymous manner. Ethical approvals and data release agreements will be obtained as required by local regulations.

Leber Hereditary Optic Neuropathy (LHON)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by Santhera Pharmaceuticals:

Primary Outcome Measures:
  • Visual acuity [ Time Frame: average 0 to 10 years (retrospective) ] [ Designated as safety issue: No ]
    The Entire duration of the disease patient by patient basis up to the date of completion of the Case Report Form (CRF).

Enrollment: 306
Study Start Date: August 2013
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Patients with LHON


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with genetically confirmed diagnosis of LHON

Inclusion Criteria:

  • patients with genetically confirmed diagnosis of LHON
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01892943

University Hospitals Leuven
Leuven, Belgium, 3000
Glostrup Hospital/National Eye Clinic of the Kennedy Center/University of Copenhagen Department of Ophthalmology
Glostrup, Denmark, 2600
CHU Bordeaux
Bordeaux, France, 33000
CIC/CMR CHNO des Quinze-Vingts
Paris, France, 75012
Universty of Bari
Bari, Italy, 70100
Fondazione G.B. Bietti
Rome, Italy, 000199
San Raffaele Hospital
Segrate, Italy, 20132
University Eye Clinic
Ljubljana, Slovenia, 1000
Sponsors and Collaborators
Santhera Pharmaceuticals
European Vision Institute Clinical Research Network
Principal Investigator: Jose-Alain Sahel, MD Centre de Recherche Institut de la Vision INSERMN
  More Information

Responsible Party: Santhera Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01892943     History of Changes
Other Study ID Numbers: LHON HCR 
Study First Received: June 26, 2013
Last Updated: May 14, 2014
Health Authority: Belgium: Ethics Committee

Additional relevant MeSH terms:
Optic Atrophy, Hereditary, Leber
Eye Diseases, Hereditary
Optic Atrophies, Hereditary
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Metabolic Diseases
Mitochondrial Diseases
Nervous System Diseases
Neurodegenerative Diseases
Optic Atrophy

ClinicalTrials.gov processed this record on May 26, 2016